Related Experiment Video
Updated: Jan 28, 2026

Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish
Published on: May 15, 2021
Vancomycin Removal During High-Volume Peritoneal Dialysis in Acute Kidney Injury Patients
Daniela Ponce1,2, Welder Zamoner3, Fernanda Moreira Freitas3
1São Paulo State University - UNESP, Botucatu, São Paulo, Brazil dponce@fmb.unesp.br.
Abstract:
Studies on vancomycin pharmacokinetics in acute kidney injury (AKI) patients on high-volume peritoneal dialysis (HVPD) are lacking. We studied the pharmacokinetics of intravenous (IV) vancomycin in AKI patients treated by HVPD who received a prescribed single IV dose of vancomycin (15 - 20 mg/kg total body weight) to determine the extent of vancomycin removal and to establish vancomycin dosing guidelines for the empirical treatment of AKI patients receiving HVPD. The application of 18 mg/kg vancomycin every 48 - 72 hours in AKI patients undergoing HVPD was required to maintain therapeutic concentrations.
Related Concept Videos
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Acute Kidney Injury I: Introduction
Acute Kidney Injury II: Pathophysiology
Peritoneal Dialysis I: Introduction and Procedure
Acute Kidney Injury VI: Nursing Management

